Income Statement BIOSTAXPAR

Stocks

BTAX

US45252A3059

Market Closed - OTC Markets 14:45:14 2026-09-09 EDT			5-day change	1st Jan Change
0.000200 ^USD	+100.00%		0.00%	+100.00%

03-27	Callan Jmb Inc. Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2B/3 Advancement in A Collaboration Led by Difgen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp and Sgp Holdings	CI
03-25	DifGen Pharmaceuticals and Aveva Drug Delivery Systems Form Strategic Platform Collaboration with Biostax Corp D/B/A Attune Biotech, SGP Holdings, and Callan JMB	CI

253d40c21b15c1788e5d1fa0e9fa.W859MaNKpcbFJAkteHB_VwNEH4ojLOQnPuVS2JYvv88.Dq0-Re0cnJekc1x9CwMGIU8nLM4XZrFOfIwcqNthyZUBoy1-whzr_pZhUA

Published financial data: BIOSTAXPAR

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Revenues	-	-	-	-	-
Total Revenues	-	-	-	-	-
Cost of Goods Sold, Total	-	-	-	-	-
Gross Profit	-	-	-	-	-
Selling General & Admin Expenses, Total	2.5M	760K	586K	1.15M	957K
R&D Expenses	336K	126K	153K	14.24K	528K
Depreciation & Amortization - (IS)	2.07K	639	-	-	-
Other Operating Expenses, Total	2.84M	887K	738K	1.16M	1.48M
Operating Income	-2.84M	-887K	-738K	-1.16M	-1.48M
Interest Expense, Total	-894K	-653K	-211K	-120K	-126K
Net Interest Expenses	-894K	-653K	-211K	-120K	-126K
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	-	-	-	-	-
Other Non Operating Income (Expenses)	-46.74K	-374K	1.18M	3.17M	-
EBT, Excl. Unusual Items	-3.78M	-1.91M	229K	1.88M	-1.61M
Gain (Loss) On Sale Of Investments	-	-	2.64M	-2.64M	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-	-	-	-	-
Other Unusual Items	382K	3.5M	712K	-2.77M	-40K
EBT, Incl. Unusual Items	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Earnings From Continuing Operations	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Net Income to Company	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Minority Interest	-	-	-	-	-
Net Income - (IS)	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Net Income to Common Incl Extra Items	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Net Income to Common Excl. Extra Items	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Per Share Items
Net EPS - Basic	-7.42	3.33	7.43	-0.1	-0.02
Basic EPS - Continuing Operations	-7.42	3.33	7.43	-0.1	-0.02
Basic Weighted Average Shares Outstanding	458K	477K	483K	36.29M	83.51M
Net EPS - Diluted	-7.42	3.33	0.38	-0.1	-0.02
Diluted EPS - Continuing Operations	-7.42	3.33	0.38	-0.1	-0.02
Diluted Weighted Average Shares Outstanding	458K	477K	9.39M	36.29M	85.13M
Normalized Basic EPS	-5.16	-2.51	0.3	0.03	-0.01
Normalized Diluted EPS	-5.16	-2.51	0.02	0.03	-0.01
Supplemental Items
EBITDA	-2.84M	-886K	-738K	-	-1.43M
EBITA	-2.84M	-887K	-738K	-1.16M	-1.43M
EBIT	-2.84M	-887K	-738K	-1.16M	-1.48M
EBITDAR	-2.82M	-883K	-	-	-
Normalized Net Income	-2.36M	-1.2M	143K	1.18M	-1.01M
Interest on Long-Term Debt	-	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	131K	-	-	-	-
Research And Development Expense From Footnotes	336K	126K	153K	14.24K	528K
Net Rental Expense, Total	12.66K	3K	-	-	-
Imputed Operating Lease Interest Expense	16.88K	3.74K	-	-	-
Imputed Operating Lease Depreciation	-4.22K	-736	-	-	-
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	131K	-	-	-	-
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	131K	-	-	-	-

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Assets
Cash And Equivalents	4.92K	9.97K	494K	150K	29.78K
Short Term Investments	-	-	2.64M	-	-
Total Cash And Short Term Investments	4.92K	9.97K	3.14M	150K	29.78K
Accounts Receivable, Total	-	-	-	-	-
Total Receivables	-	-	-	-	-
Inventory	-	-	-	-	-
Prepaid Expenses	-	-	-	-	-
Total Current Assets	4.92K	9.97K	3.14M	150K	29.78K
Gross Property Plant And Equipment	13.21K	13.21K	-	-	-
Accumulated Depreciation	-12.52K	-13.21K	-	-	-
Net Property Plant And Equipment	691	0	-	-	-
Other Intangibles, Total	-	-	-	762K	708K
Other Long-Term Assets, Total	200	200	-	50.73K	5.5K
Total Assets	5.82K	10.17K	3.14M	964K	743K
Liabilities
Accounts Payable, Total	2.66M	2.56M	2.18M	1.3M	1.35M
Accrued Expenses, Total	4.56M	4.92M	5.03M	537K	624K
Short-term Borrowings	-	-	3.79M	696K	1.18M
Current Portion of Long-Term Debt	5.55M	2.84M	-	-	-
Other Current Liabilities	934K	1.35M	91.17K	944K	1.4M
Total Current Liabilities	13.69M	11.68M	11.09M	3.48M	4.56M
Long-Term Debt	-	-	-	-	-
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	13.69M	11.68M	11.09M	3.48M	4.56M
Common Stock, Total	46	48	49	8.3K	8.37K
Additional Paid In Capital	371M	371M	371M	380M	381M
Retained Earnings	-385M	-383M	-379M	-383M	-385M
Comprehensive Income and Other	10.3K	10.3K	10.3K	10.3K	-1
Total Common Equity	-13.69M	-11.67M	-7.95M	-2.51M	-3.82M
Minority Interest	-	-	-	-	-
Total Equity	-13.69M	-11.67M	-7.95M	-2.51M	-3.82M
Total Liabilities And Equity	5.82K	10.17K	3.14M	964K	743K
Supplemental Items
ECS Total Shares Outstanding on Filing Date	458K	482K	484K	83.3M	83.74M
ECS Total Common Shares Outstanding	458K	477K	484K	83.05M	83.66M
Book Value / Share	-29.92	-24.48	-16.43	-0.03	-0.05
Tangible Book Value	-13.69M	-11.67M	-7.95M	-3.28M	-4.52M
Tangible Book Value Per Share	-29.92	-24.48	-16.43	-0.04	-0.05
Total Debt	5.55M	2.84M	3.79M	696K	1.18M
Net Debt	5.54M	2.83M	647K	546K	1.15M
Debt Equivalent Oper. Leases	101K	24K	-	-	-
Minority Interest, Total (Incl. Fin. Div)	-	-	-	-	-
Account Code - Inventory Valuation	5	3	3	3	3
Machinery, Total	13.21K	13.21K	-	-	-
Full Time Employees	-	-	-	-	-

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Net Income	-3.4M	1.59M	3.59M	-3.54M	-1.65M
Depreciation & Amortization - CF	2.07K	639	-	-	-
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	-	54.31K
Depreciation & Amortization, Total	2.07K	639	-	-	54.31K
Amortization of Deferred Charges, Total - (CF)	222K	162K	34.79K	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-2.64M	2.64M	-
Asset Writedown & Restructuring Costs	-	-	-	-	-
(Income) Loss On Equity Investments - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	131K	-	-	-	-
Provision and Write-off of Bad Debts	-	-	-	-	-
Other Operating Activities, Total	-310K	-2.96M	-1.89M	-393K	300K
Change In Accounts Receivable	-	-	-	-	-
Change In Inventories	82.8K	-	-	-	-
Change In Accounts Payable	895K	99.23K	104K	389K	50.62K
Change in Other Net Operating Assets	2.37M	913K	579K	314K	589K
Cash from Operations	-934	-192K	-232K	-582K	-657K
Capital Expenditure	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-500K	-
Cash from Investing	-	-	-	-500K	-
Short Term Debt Issued, Total	-	-	716K	738K	536K
Long-Term Debt Issued, Total	-	197K	-	-	-
Total Debt Issued	-	197K	716K	738K	536K
Long-Term Debt Repaid, Total	-	-	-	-	-
Total Debt Repaid	-	-	-	-	-
Issuance of Common Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	-	-	-
Cash from Financing	-	197K	716K	738K	536K
Miscellaneous Cash Flow Adjustments	-	-	-	-	1
Net Change in Cash	-934	5.05K	484K	-343K	-121K
Supplemental Items
Cash Interest Paid	16K	-	-	-	-
Levered Free Cash Flow	100K	-116K	-2.09M	-5.82M	-358K
Unlevered Free Cash Flow	437K	129K	-1.99M	-5.75M	-279K
Change In Net Working Capital	-2.08M	-683K	1.53M	4.52M	-594K
Net Debt Issued / Repaid	-	197K	716K	738K	536K

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Profitability
Return on Assets	-3.64K	-6.94K	-29.3	-35.45	-108.73
Return on Total Capital	24.97	6.54	7.11	24.32	41.72
Return On Equity %	27.24	-12.53	-36.56	67.6	52.16
Return on Common Equity	27.24	-12.53	-36.56	67.6	52.16
Margin Analysis
Gross Profit Margin %	-	-	-	-	-
SG&A Margin	-	-	-	-	-
EBITDA Margin %	-	-	-	-	-
EBITA Margin %	-	-	-	-	-
EBIT Margin %	-	-	-	-	-
Income From Continuing Operations Margin %	-	-	-	-	-
Net Income Margin %	-	-	-	-	-
Net Avail. For Common Margin %	-	-	-	-	-
Normalized Net Income Margin	-	-	-	-	-
Levered Free Cash Flow Margin	-	-	-	-	-
Unlevered Free Cash Flow Margin	-	-	-	-	-
Asset Turnover
Asset Turnover	-	-	-	-	-
Fixed Assets Turnover	-	-	-	-	-
Inventory Turnover (Average Inventory)	-	-	-	-	-
Short Term Liquidity
Current Ratio	0	0	0.28	0.04	0.01
Quick Ratio	0	0	0.28	0.04	0.01
Operating Cash Flow to Current Liabilities	-0	-0.02	-0.02	-0.17	-0.14
Days Outstanding Inventory (Average Inventory)	-	-	-	-	-
Average Days Payable Outstanding	-	-	-	-	-
Long Term Solvency
Total Debt/Equity	-40.51	-24.38	-47.63	-27.71	-31.03
Total Debt / Total Capital	-68.1	-32.25	-90.95	-38.33	-44.99
LT Debt/Equity	-	-	-	-	-
Long-Term Debt / Total Capital	-	-	-	-	-
Total Liabilities / Total Assets	235K	115K	353.22	360.81	613.22
EBIT / Interest Expense	-3.17	-1.36	-3.5	-9.66	-11.82
EBITDA / Interest Expense	-3.17	-1.36	-3.5	-	-11.39
(EBITDA - Capex) / Interest Expense	-3.17	-1.36	-3.5	-	-11.39
Total Debt / EBITDA	-1.96	-3.21	-5.13	-	-0.83
Net Debt / EBITDA	-1.95	-3.2	-0.88	-	-0.81
Total Debt / (EBITDA - Capex)	-1.96	-3.21	-5.13	-	-0.83
Net Debt / (EBITDA - Capex)	-1.95	-3.2	-0.88	-	-0.81
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	-
Gross Profit, 1 Yr. Growth %	-	-	-	-	-
EBITDA, 1 Yr. Growth %	-30.54	-68.74	-16.79	-	-
EBITA, 1 Yr. Growth %	-30.52	-68.75	-16.78	57.62	22.96
EBIT, 1 Yr. Growth %	-30.52	-68.75	-16.78	57.62	27.63
Earnings From Cont. Operations, 1 Yr. Growth %	-60.62	-146.77	125.73	-198.61	-53.32
Net Income, 1 Yr. Growth %	-58.45	-146.77	125.73	-198.61	-53.32
Normalized Net Income, 1 Yr. Growth %	-14.68	-49.36	-111.97	721	-185.61
Diluted EPS Before Extra, 1 Yr. Growth %	-60.99	-144.91	-88.6	-126.32	-80
Inventory, 1 Yr. Growth %	-	-	-	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-75.02	-100	-	-	-
Total Assets, 1 Yr. Growth %	-93.65	74.88	30.76K	-69.3	-22.85
Tangible Book Value, 1 Yr. Growth %	21.67	-14.77	-31.87	-58.78	38.09
Common Equity, 1 Yr. Growth %	21.67	-14.77	-31.87	-68.38	51.81
Cash From Operations, 1 Yr. Growth %	-99.93	20.45K	20.71	151.09	12.84
Capital Expenditures, 1 Yr. Growth %	-	-	-	-	-
Levered Free Cash Flow, 1 Yr. Growth %	-104.64	-215.99	1.69K	178.7	-93.86
Unlevered Free Cash Flow, 1 Yr. Growth %	-123.68	-70.37	-1.64K	188.49	-95.14
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	-	-	-
Gross Profit, 2 Yr. CAGR %	-	-	-	-	-
EBITDA, 2 Yr. CAGR %	-27.01	-53.41	-49	-	39.28
EBITA, 2 Yr. CAGR %	-26.99	-53.4	-49	14.53	39.22
EBIT, 2 Yr. CAGR %	-26.99	-53.4	-49	14.53	41.83
Earnings From Cont. Operations, 2 Yr. CAGR %	-34.57	-57.08	2.75	49.19	-32.16
Net Income, 2 Yr. CAGR %	-31.86	-55.92	2.75	49.19	-32.16
Normalized Net Income, 2 Yr. CAGR %	-30.45	-34.27	-75.38	-0.85	165.12
Diluted EPS Before Extra, 2 Yr. CAGR %	-42.96	-58.14	-77.37	-82.68	-77.06
Net Property, Plant and Equip., 2 Yr. CAGR %	-47.73	-	-	-	-
Total Assets, 2 Yr. CAGR %	-82.75	-66.68	2.22K	873.4	-51.33
Tangible Book Value, 2 Yr. CAGR %	45.18	1.83	-23.8	-47.01	-24.56
Common Equity, 2 Yr. CAGR %	45.18	1.83	-23.8	-53.59	-30.71
Cash From Operations, 2 Yr. CAGR %	-97.87	-62.56	1.48K	74.1	68.33
Capital Expenditures, 2 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 2 Yr. CAGR %	-56.27	-76.8	356.16	607.09	-58.62
Unlevered Free Cash Flow, 2 Yr. CAGR %	121.33	-73.51	113.52	566.27	-62.56
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-	-	-
Gross Profit, 3 Yr. CAGR %	-	-	-	-	-
EBITDA, 3 Yr. CAGR %	-33.26	-44.98	-43.47	-	17.3
EBITA, 3 Yr. CAGR %	-33.25	-44.97	-43.46	-25.71	17.27
EBIT, 3 Yr. CAGR %	-33.25	-44.97	-43.46	-25.71	18.74
Earnings From Cont. Operations, 3 Yr. CAGR %	-44.45	-41.5	-25.37	1.35	1.28
Net Income, 3 Yr. CAGR %	-44.17	-39.9	-24.02	1.35	1.28
Normalized Net Income, 3 Yr. CAGR %	-39.71	-37.43	-62.74	-20.75	-5.59
Diluted EPS Before Extra, 3 Yr. CAGR %	-56.49	-47.33	-72.87	-76.21	-81.83
Net Property, Plant and Equip., 3 Yr. CAGR %	-27.98	-	-	-	-
Total Assets, 3 Yr. CAGR %	-57.63	-62.67	224.78	449.26	318.12
Tangible Book Value, 3 Yr. CAGR %	38.67	21.56	-10.94	-37.91	-27.08
Common Equity, 3 Yr. CAGR %	38.67	21.56	-10.94	-43.16	-31.1
Cash From Operations, 3 Yr. CAGR %	-93.1	-54.61	-44.69	754.05	50.67
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 3 Yr. CAGR %	-2.34	-39.47	-1.17	287.07	45.37
Unlevered Free Cash Flow, 3 Yr. CAGR %	-25.51	13.22	2.59	136.05	29.21
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-37.91	-38.33	-40.07	-	-18.92
EBITA, 5 Yr. CAGR %	-37.9	-38.32	-40.06	-26.22	-18.93
EBIT, 5 Yr. CAGR %	-39	-39.03	-40.06	-26.22	-18.32
Earnings From Cont. Operations, 5 Yr. CAGR %	-41.59	-37.72	-28.96	-14.93	-28.16
Net Income, 5 Yr. CAGR %	-41.18	-35.51	-28.74	-13.53	-27.39
Normalized Net Income, 5 Yr. CAGR %	-35.19	-21.73	-57.86	-24.78	-18.32
Diluted EPS Before Extra, 5 Yr. CAGR %	-56.74	-48.6	-66.5	-66.24	-74.63
Net Property, Plant and Equip., 5 Yr. CAGR %	-30.41	-	-	-	-
Total Assets, 5 Yr. CAGR %	-75.09	-24.42	110.23	37.58	52
Tangible Book Value, 5 Yr. CAGR %	27.44	24.77	9.13	-12.79	-16.66
Common Equity, 5 Yr. CAGR %	50.96	24.77	9.13	-17.29	-19.45
Cash From Operations, 5 Yr. CAGR %	-81.07	-41.63	-39.42	-22.29	-13.67
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 5 Yr. CAGR %	-58.46	0.33	80.91	61.81	-30.23
Unlevered Free Cash Flow, 5 Yr. CAGR %	-44.55	-14.53	13.51	130.05	-31.45